AXNX News and Press, Axonics Modulation Technologies Inc. From 06/29/23

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2023 financial results after the close of trading on Thursday, July 27. Axonics will host a co...

2023-05-12 08:48:10 ET Summary AXNX reported impressive 1Q23 earnings with revenue of $70.7 million, representing a remarkable 46% year-on-year growth. The success of Axonics' F15 and Bulkamid products played a significant role in driving their strong performance. AXNX raised ...

2023-05-10 09:41:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Small Cap Fund® (the Fund) was up 9.44% (Institutional Shares) in the first...

2023-05-09 13:25:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Discovery Fund® (the Fund) was up 11.20% compared...

2023-05-04 06:22:39 ET Summary Axonics is under pressure after Q1 results came in solid but guidance didn't increase as much as hoped. The company has 2 solid products and the medical technology space has performed well recently. AXNX is a volatile small cap but the recent wea...

2023-05-01 21:36:06 ET Axonics, Inc. (AXNX) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Chris Pasquale - Nephron...

2023-05-01 17:08:29 ET Axonics Modulation Technologies press release ( NASDAQ: AXNX ): Q1 GAAP EPS of -$0.19. Revenue of $70.7M (+46.0% Y/Y). Gross margin was 74.3% in 1Q23 compared to 68.7% in the prior year period. Operating expenses were $66.9 million in 1Q23 an...

Generated quarterly revenue of $70.7 million, an increase of 46% year over year Fiscal year 2023 revenue guidance increased to $348 million Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment o...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following upcoming investor conferences: Event: BofA Securities Healthcare Conference ...

2023-04-24 06:22:01 ET Axonics ( NASDAQ: AXNX ) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian from Intermed Labs for undisclosed terms. SNM is a...